Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Investors in Nevro Corp (Symbol: NVRO) saw new options become available this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVRO ...

Nevro Corp. NVRO recently announced the publication of new data in the journal, Medical Devices: Evidence and Research, demonstrating the superiority of the Nevro1 sacroiliac (SI) Joint Fusion ...

Nevro Corp. NVRO reported a loss per share of 53 cents in the second quarter of 2024, narrower than the year-ago quarter’s loss of 69 cents. The metric beat the Zacks Consensus Estimate of a ...

Therefore, let’s take a closer look at what smart money thinks about Nevro Corp (NYSE:NVRO). Video: Watch our video about the top 5 most popular hedge fund stocks. At the moment there are a ...

The stock price of Nevro (NASDAQ: NVRO), a medical devices company, has seen a large 22% fall in a month. This can largely be attributed to the outcome of a lawsuit against Nevro for patent ...

In addition to specific proprietary factors, Trade-Ideas identified Nevro as such a stock due to the following factors: NVRO has an average dollar-volume (as measured by average daily share volume ...

The market expects Nevro (NVRO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2021. This widely-known consensus outlook ...